Contact Professor Zaheer Babar Z.Babar@hud.ac.uk
In October 2016, the Austrian Public Health Institute published a comparison of prices of 60 high-cost medicines in Austria and the other Member States of the EU.
Key findings: The analysis showed that in comparison to other European countries Austrian prices of the surveyed medicines used in hospitals are higher than those of the selected out-patient medicines. A second key finding was that the Austrian pharmacy retail prices of surveyed medicines rank comparably higher in EU comparison than Austrian ex-factory prices or pharmacy purchasing prices. This suggests a possible need for action for Austrian policy-makers to optimize the pharmaceutical pricing system with particular attention on the areas of medicines used in hospitals (with no price regulation) and to pharmacy remuneration.
The full study (in German with an English Executive Summary) is available at: http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/GOeG_Preisstudie2015_Publikation%200-Fehler.pdf
A brief report in English is available at: http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/GOeG_Preisstudie2015_Kurzbericht_EN.%200-Fehler.pdf
A new study published by World Health Organization (WHO) and our WHO Collaborating Centre in Vienna finds Sofosbuvir globally unaffordable.
More information here:
In this new article the authors (staff of our WHO Collaborating Centre) analysed preferences of eight stakeholder groups (patients, consumers, competent authorities for pharmaceutical P & R, public payers, research-oriented industry, generic medicines industry, pharmacists, doctors) towards policy objectives and pharmaceutical pricing and reimbursement measures in accordance with their preferred objectives.
More information here:
The Piperska Group and the WHO Collaborating Centre for Research and Training in Pharmacoepidemiology, Spain are organising the Second Course on Interface Management of Pharmacotherapy on October 17-19 2016 in Barcelona.
More information here:
The study aims to analyse the policy options of 'external price referencing' (EPR) and 'differential pricing' (DP) in terms of technical, economic and legal considerations, in order to investigate possible benefits from improved cross-country policy coordination in the area of pharmaceutical pricing.
This study was performed by a consortium composed of Gesundheit Österreich Forschungs- und Planungs GmbH (GÖ FP, project leader) and SOGETI Luxembourg S.A. (consortium leader), together with the University for Health Sciences, Medical Informatics and Technology (UMIT) as sub-contractor related to the legal analysis and was funded by the Health Programme of the European Union.
Executive summary in German: http://ec.europa.eu/health/systems_performance_assessment/docs/pharmaproductpricing_exe_de.pdf
he WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies in Vienna and WHO, Regional Office for Europe offer a one-week training course (29 Aug. - 2 Sep. 1016) for professionals working in the field of pricing and reimbursement of medicines. International scientific experts and experienced national policy-makers will provide insights into pharmaceutical policies related to medicine pricing and reimbursement, and further policies before, at and after the launch of new medicines.
The summer school provides lectures, hands-on training sessions, panel discussions with high-level experts, case studies on implementation and optimization of pharmaceutical policies, and study visits.
More Information will follow soon on this website.
The 3rd International PPRI Conference titled ‘Pharmaceutical Pricing and Reimbursement Policies: Challenges beyond the Financial Crisis’ was held in Vienna on 12-13 October 2015. Conclusions of the conference were now published in the Journal of Pharmaceutical Policy and Practice: http://joppp.biomedcentral.com/articles/10.1186/s40545-016-0056-8
The Division of Pharmacoepidemiology and Clinical Pharmacology at Utrecht University, the Netherlands (WHO Collabrating Centre for Pharmaceutical Policy and Regulation), offers three international summer courses:
4-8 July 2016: Pharmacoepidemiology & Drug Safety
11-15 July 2016: Pharmaceutical Policy Analysis (in collaboration with WHO)
18-22 July 2016: Pharmacoeconomics
More information here
A two day meeting was held at WHO Headquarters in Geneva in November 2015 to discuss the use of health technology assessment (HTA) for universal health coverage and reimbursement, as a follow-up to a small consultation held in July 2015. The meeting brought together experts in HTA and pharmaceutical economics from academia (including representatives of the Vienna WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement).
The report titled "Using Health Technology Assessment for Universal Health Coverage and Reimbursement Systems" summarizes the outcomes of the meetings and lists the identified priority areas of further work for WHO, e.g. supporting the development of appropriate principles to use HTA in health systems and decision-making.